Phenobarbital induces the 2-hydroxylation of desipramine

Therapeutic Drug Monitoring

Volumn 18, Issue 1, 1996, Pages 60-64

  Spina, E ^a,b   Avenoso, A ^a   Campo, G M ^a   Caputi, A P ^a   Perucca, E ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Psychiatric Hospital   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

CYP2D6; Desipramine; Enzyme induction; Hydroxylation; Phenobarbital

Indexed keywords

2 HYDROXYDESIPRAMINE; CARBAMAZEPINE; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; PHENOBARBITAL; PHENYTOIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG URINE LEVEL; EPILEPSY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; DESIPRAMINE; ENZYME INDUCTION; EPILEPSY; HALF-LIFE; HUMANS; HYDROXYLATION; MALE; MIXED FUNCTION OXYGENASES; PHENOBARBITAL; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0030040670     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199602000-00010     Document Type: Article

References (26)

1. Gram LF. Metabolism of tricyclic antidepressants. Dan Med Bull 1974;21:218-31.
2. Spina E, Birgersson C, von Bahr C, et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984;36:677-82.
3. Birgersson C, Morgan ET, Jornvall H, von Bahr C. Purification of desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver. Biochem Pharmacol 1986;35:3165-6.
4. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3: 61-70.
5. Brosen K, Gram LF. Clinical significance of the sparteine/ debrisoquin oxidation polymorphism. Eur J din Pharmacol 1989;36:537-47.
6. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism. Clinical aspects. Pharmacol Ther 1990;46:377-94.
7. Zanger UM, Vilbois F, Hardwick JP, Meyer UA. Absence of hepatic cytochrome P450bfI causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988;27:5447-54.
8. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986;22:49-53.
9. Syvalahti EKG, Lindberg R, Kallio J, De Vocht M. Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 1986;22:89-92.
10. Leclercq V, Desager JP, Horsmans Y, van Nieuwenhuyze Y, Harvengt C. Influence of rifampicin, phenobarbital and cimetidine on mixed function mono-oxygenase in extensive and poor metabolizers of debrisoquine. Int J Clin Pharmacol Ther Toxicol 1989;27:593-8.
11. Alexanderson B, Evans PAB, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969;4:764-8.
12. Burrows GD, Davies B. Antidepressants and barbiturates. Br Med J 1971;4:113.
13. Braithwaite RA, Flanagan RA, Richens A. Steady-state plasma nortriptyline concentrations in epileptic patients. Br J Clin Pharmacol 1975;2:469-71.
14. Hewick DS, Sparks RG, Stevenson IH, Watson ID. Induction of imipramine metabolism following barbiturate administration. Br J Clin Pharmacol 1977;4:339.
15. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
16. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 1991;11: 313-8.
17. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology 1995;17:413-6.
18. Mahgoub A, Idle JR, Dring LJ, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
19. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985;38:618-24.
20. Brosen K, Gram LF. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1988;43:400-6.
21. Sutfin TA, Jusko WJ. High-performance liquid chromatography assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J Pharm Sci 1979;68:703-5.
22. Spina E, Campo GM, Avenoso A, Pollicino AM, Caputi AP. Effect of buspirone or zopiclone on plasma concentrations of imipramine and desipramine in depressed patients. Eur Bull Drug Res 1992;1:37-40.
23. Nakazawa K. Studies on the demethylation, hydroxylation and N-oxidation of imipramine in rat liver. Biochem Pharmacol 1970;19:1363-9.
24. Brosen K. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18:220-39.
25. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987;33:133-44.
26. Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993;15: 258-60.